ELISpot And FluoroSpot Assay Market Size

ELISpot And FluoroSpot Assay Market Analysis

The ELISpot and FluoroSpot assay market is expected to register a CAGR of 13.3% during the forecast period.

• The COVID-19 pandemic significantly impacted healthcare systems worldwide, including the ELISpot and FluoroSpot assay markets. A 2020 article by Medtech suggested a link between antibody titers and T-cell responsiveness in COVID-19. The strongest T-cell response was observed in three individuals (C4, C5, and C7), with the lowest antibody response in COVID-19 patients, as measured by the FluoroSpot assay. ELISpot and FluoroSpot assays are commonly used to assess SARS-CoV-2-specific T- and B-cell immunity in COVID-19 patients. However, since COVID-19 cases declined last year, the market has reported a slight decline. Nevertheless, the market is expected to show a stable growth rate during the forecast period.
• The ELISpot and FluoroSpot assay market is expected to grow due to several factors. Firstly, rising vaccine research to tackle drug-resistant strains, the growing global occurrence of chronic illnesses, and technological innovations in ELISpot and FluoroSpot analyzers and assay kits are expected to drive market growth. ELISpot is a critical tool in vaccine development for various illnesses, including acquired immunodeficiency syndrome (AIDS), tuberculosis, malaria, cancer, and flu. The ELISpot test is widely utilized in clinical studies to evaluate vaccines. In a June 2021 article published in BMC Infectious Diseases Journal, the FluoroSpot assay based on the ELISpot was more accurate than enzyme-linked immunoassay (ELISA) or flow cytometry (FCM). Therefore, these assays are given priority to ensure precision in research diagnostics.
• The prevalence of chronic diseases is also expected to boost the market growth of ELISpot and FluoroSpot assays. According to the Canadian Cancer Statistics November 2021 report, an estimated 2 in 5 Canadians were likely to be diagnosed with cancer in their lifetime. An estimated 229,200 Canadians are predicted to have been diagnosed with cancer in 2021. Furthermore, non-communicable diseases (NCDs) kill 41 million people globally each year, equivalent to 71% of all deaths, according to an April 2021 update by the World Health Organization (WHO). More than 15 million people die from NCDs between the ages of 30 and 69 years, with 85% of these premature deaths occurring in low- and middle-income countries. Consequently, the increasing prevalence of chronic diseases is expected to increase the utility of ELISpot and FluroSpot assays for diagnosis purposes, propelling the market growth.
• The strategic initiatives adopted by key players, such as product launches, approvals, partnerships, and research studies, are also expected to drive market growth. For instance, in April 2021, Ardigen and ImmuMap launched a research collaboration focused on identifying T-cell receptors (TCRs) reactive to tumor-associated neoantigens. The collaboration involves ELISpot assays, next-generation sequencing (NGS), MHC multimer labeling and sorting, and 10x Genomics Single Cell Immune Profiling. Such developments are expected to spur innovation in the assays and ultimately augment market growth.
• In conclusion, the ELISpot and FluoroSpot market is expected to witness tremendous growth over the forecast period due to factors such as the rising prevalence of chronic diseases and technological advancements by key players. However, the availability of alternative detection technologies is likely to impede market growth.